[go: up one dir, main page]

CY1113286T1 - COMPOSITION WITH STRONTIUM AND VITAMIN D FOR PREVENTION Ή / TREATMENT OF STRAW Ή / BONE DISEASES - Google Patents

COMPOSITION WITH STRONTIUM AND VITAMIN D FOR PREVENTION Ή / TREATMENT OF STRAW Ή / BONE DISEASES

Info

Publication number
CY1113286T1
CY1113286T1 CY20121101032T CY121101032T CY1113286T1 CY 1113286 T1 CY1113286 T1 CY 1113286T1 CY 20121101032 T CY20121101032 T CY 20121101032T CY 121101032 T CY121101032 T CY 121101032T CY 1113286 T1 CY1113286 T1 CY 1113286T1
Authority
CY
Cyprus
Prior art keywords
treatment
strontium
bone
straw
vitamin
Prior art date
Application number
CY20121101032T
Other languages
Greek (el)
Inventor
Stephan Christgau
Christian Hansen
Henrik Nilsson
Original Assignee
Osteologix A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osteologix A/S filed Critical Osteologix A/S
Publication of CY1113286T1 publication Critical patent/CY1113286T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Συνδυασμένη θεραπευτική αντιμετώπιση, όπου μια ένωση που περιέχει στρόντιο μαζί με μία ή περισσότερες δραστικές ουσίες ικανές μείωσης της συχνότητας των καταγμάτων των οστών ή/και αύξησης της πυκνότητας οστών ή/και βελτίωσης της ίασης του σπασμένου οστού ή/και βελτίωσης της ποιότητας των οστών χορηγούνται για χρήση στη θεραπευτική αντιμετώπιση ή/και την προφύλαξη των παθήσεων των χόνδρων ή/και των οστών.Combined treatment, wherein a strontium-containing compound together with one or more active substances capable of reducing the frequency of bone fractures and / or increasing bone density and / or improving broken bone healing and / or improving bone quality is administered for use in the treatment and / or prophylaxis of cartilage and / or bone diseases.

CY20121101032T 2003-05-07 2012-10-30 COMPOSITION WITH STRONTIUM AND VITAMIN D FOR PREVENTION Ή / TREATMENT OF STRAW Ή / BONE DISEASES CY1113286T1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200300691 2003-05-07
DKPA200300931 2003-06-20
US52854803P 2003-12-09 2003-12-09
DKPA200301819 2003-12-09
EP10185878A EP2266584B1 (en) 2003-05-07 2004-05-06 Composition with strontium and vitamin D for the prophylaxis and/or treatment of cartilage and/or bone conditions

Publications (1)

Publication Number Publication Date
CY1113286T1 true CY1113286T1 (en) 2016-04-13

Family

ID=45604595

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20121101030T CY1113264T1 (en) 2003-05-07 2012-10-30 STRONTIUM COMBINATIONS FOR THE PREVENTION / TREATMENT OF cartilage and / or bone diseases
CY20121101032T CY1113286T1 (en) 2003-05-07 2012-10-30 COMPOSITION WITH STRONTIUM AND VITAMIN D FOR PREVENTION Ή / TREATMENT OF STRAW Ή / BONE DISEASES

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20121101030T CY1113264T1 (en) 2003-05-07 2012-10-30 STRONTIUM COMBINATIONS FOR THE PREVENTION / TREATMENT OF cartilage and / or bone diseases

Country Status (12)

Country Link
US (2) US20060275503A1 (en)
EP (2) EP1622630B1 (en)
JP (2) JP4861817B2 (en)
AU (2) AU2004237438B2 (en)
CA (1) CA2524610C (en)
CY (2) CY1113264T1 (en)
DK (2) DK2266584T3 (en)
ES (2) ES2393781T3 (en)
PL (2) PL1622630T3 (en)
PT (4) PT1745791E (en)
SI (2) SI2266584T1 (en)
WO (1) WO2004098618A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1745791E (en) * 2003-05-07 2013-07-23 Osteologix As Treating cartilage/bone conditions with water-soluble strontium salts
DE602004002832T2 (en) * 2003-05-07 2007-06-06 Osteologix A/S TREATMENT OF CARTILAGE / BONE DISEASES WITH WATER-SOLUBLE STRONTIUM SALTS
AU2005216596B2 (en) 2004-02-26 2011-03-24 Osteologix A/S Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions
WO2005108339A2 (en) 2004-05-06 2005-11-17 Osteologix A/S High yield and rapid syntheses methods for producing metallo-organic salts
JP2008502609A (en) * 2004-06-17 2008-01-31 オステオロジックス エイ／エス Methods for improving treatment of rheumatoid arthritis and joint diseases
WO2006089546A1 (en) * 2005-02-28 2006-08-31 Osteologix A/S Tablets comprising a high load of strontium
KR20070034075A (en) 2004-06-25 2007-03-27 스트론틴 에이피에스 Compositions containing strontium and vitamin D and uses thereof
ES2525497T3 (en) 2004-10-08 2015-10-09 Forward Pharma A/S Pharmaceutical controlled release compositions comprising a fumaric acid ester
US20090137678A1 (en) * 2005-07-06 2009-05-28 Stephan Christgau High yield synthesis methods for producing organic salts of strontium
FR2899895B1 (en) 2006-04-12 2010-09-17 Servier Lab NOVEL STRONTIUM SALTS OF SULFONIC ACIDS, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US20070292529A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating osteoporotic conditions
US20070292535A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating arthritic and or osteoporitic conditions
WO2008027880A2 (en) * 2006-08-28 2008-03-06 Brookler Kenneth H Strontium-based treatment of otosclerosis
DK2379063T4 (en) 2009-01-09 2021-05-25 Fwp Ip Aps PHARMACEUTICAL PREPARATION INCLUDING ONE OR MORE FUMARIC ACID RESIDENTS IN AN EROSION MATRIX
FR2953139B1 (en) * 2009-11-27 2012-04-13 Servier Lab PHARMACEUTICAL COMPOSITION COMPRISING STRONTIUM SALT, VITAMIN D AND CYCLODEXTRIN
ES2627692T3 (en) 2010-06-10 2017-07-31 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2012143932A1 (en) * 2011-04-21 2012-10-26 Shilpa Medicare Limited Crystalline strontium ranelate form-s
EP2530068A1 (en) 2011-05-31 2012-12-05 Lacer, S.A. New strontium salts, synthesis and use thereof in the treatment of osteoporosis
CN102372625A (en) * 2011-10-19 2012-03-14 山东恒通生物科技有限公司 Preparation method of soluble strontium citrate
EA029559B1 (en) 2011-12-14 2018-04-30 Серагон Фармасьютикалс, Инк. Fluorinated estrogen receptor modulators and use thereof
RU2512838C2 (en) * 2012-07-24 2014-04-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения и социального развития Российской Федерации Method for improving physical condition in young females
WO2018084959A2 (en) * 2016-09-30 2018-05-11 Nelson Deanna J Pharmaceutical quality strontium l-lactate
CN109293519B (en) * 2017-07-25 2021-09-28 北京斯利安药业有限公司 Preparation method of tamoxifen citrate crystal form A
CN110240630B (en) * 2019-07-05 2021-08-10 浙江海洋大学 Natural oligopeptide with liver cell oxidative damage protection effect

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB241266A (en) 1924-07-14 1925-10-14 Knoll & Co Chem Fab Improvements in the manufacture of double compounds of dimethylxanthines, earth alkali and salicylic acid
BE532864A (en) 1952-04-29
GB990957A (en) 1964-02-24 1965-05-05 Stafford Miller Ltd Strontium ion-containing toothpaste
SE340807B (en) * 1966-05-06 1971-12-06 Astra Ab
US4056567A (en) * 1976-03-08 1977-11-01 Lever Brothers Company Chemical processes for preparing citric acid
US4230700A (en) * 1977-12-07 1980-10-28 The Procter & Gamble Company Methods for inhibiting mobilization of calcium phosphate in animal tissue
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3735264C1 (en) * 1987-10-17 1988-08-25 Degussa Process for the preparation of alkaline earth metal salts of L-2-pyrrolidone-5-carboxylic acid
US5160737A (en) * 1988-05-03 1992-11-03 Perio Products Ltd. Liquid polymer composition, and method of use
FR2633619B1 (en) * 1988-06-29 1991-02-08 Adir NEW STRONTIUM SALT, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US5602116A (en) * 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
JP2893191B2 (en) * 1988-11-08 1999-05-17 武田薬品工業株式会社 Controlled release matrix agent
DE69008555T3 (en) * 1989-01-31 1998-09-17 Yissum Res Dev Co Dental composition for hypersensitive teeth.
GB8906914D0 (en) 1989-03-28 1989-05-10 Beecham Group Plc Novel compositions
FR2651497B1 (en) * 1989-09-01 1991-10-25 Adir NOVEL SALTS OF BIVALENT METALS OF N, N-DI ACID (CARBOXYMETHYL) AMINO-2 CYANO-3 CARBOXYMETHYL-4 CARBOXY-5 THIOPHENE, THEIR PREPARATION METHOD AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2658816A1 (en) * 1990-02-27 1991-08-30 Adir NOVEL ALKALINOTERREUX METAL SALTS OF OXA-POLYACIDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2665896A1 (en) 1990-08-16 1992-02-21 Rhone Poulenc Chimie Metal carboxylates, their preparation and superconducting compositions obtained from them
US5128364A (en) * 1991-03-28 1992-07-07 Merck Frosst Canada, Inc. Pyrrolo[1,2-a]indole hydroxylamine derivatives as inhibitors of leukotriene biosynthesis
HUT66379A (en) * 1991-05-28 1994-11-28 Procter & Gamble Calcium, trace mineral, vitamin d and drug therapy combinations
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
AU8083694A (en) * 1993-10-19 1995-05-08 Merck & Co., Inc. Combination of bisphosphonates and growth hormone secretagogues
RO118291B1 (en) * 1993-11-30 2003-04-30 Searle & Co PIRAZOL DERIVATIVES 1,3,4,5 - TETRASUBSTITUITIS AND PHARMACEUTICAL COMPOSITION CONTAINING CONTAINERS
US5475021A (en) * 1993-12-03 1995-12-12 Vanderbilt University Compounds and compositions for inhibition of cyclooxygenase activity
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
WO1996003392A1 (en) * 1994-07-27 1996-02-08 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5585504A (en) * 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
US5908852A (en) * 1994-11-14 1999-06-01 G. D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
JP3181190B2 (en) * 1994-12-20 2001-07-03 日本たばこ産業株式会社 Oxazole derivatives
JP2636819B2 (en) 1994-12-20 1997-07-30 日本たばこ産業株式会社 Oxazole-based heterocyclic aromatic compounds
US5686470A (en) * 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
ATE223390T1 (en) * 1995-02-13 2002-09-15 Searle & Co SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
EP0737471A3 (en) 1995-04-10 2000-12-06 L'oreal Use of alkaline earth metal salts as TNF-alpha inhibitor in a topical composition and composition obtained therefrom
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
AU6111796A (en) * 1995-06-12 1997-01-09 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5 -lipoxygenase inhibitor
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
FR2740341B1 (en) * 1995-10-26 1997-12-19 Oreal USE OF LANTHANIDE SALT, TIN, ZINC, MANGANESE, YTTRIUM, COBALT, BARIUM, STRONTIUM IN A SKIN COMPOSITION
FR2743813B1 (en) * 1996-01-23 1998-02-20 Oreal STABLE GEL COMPOSITION WITH HIGH ELECTROLYTE CONTENT
US5789413A (en) * 1996-02-01 1998-08-04 Merck Frosst Canada, Inc. Alkylated styrenes as prodrugs to COX-2 inhibitors
US5807873A (en) * 1996-04-04 1998-09-15 Laboratories Upsa Diarylmethylidenefuran derivatives and their uses in therapeutics
US5908858A (en) * 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
US5756531A (en) * 1996-04-30 1998-05-26 Abbott Laboratories Iminoxy derivatives of indole and indene compounds as inhibitors of prostaglandin biosynthesis
US5696431A (en) * 1996-05-03 1997-12-09 Philips Electronics North America Corporation Inverter driving scheme for capacitive mode protection
US5883267A (en) * 1996-05-31 1999-03-16 Merck & Co., Inc. Process for making phenyl heterocycles useful as cox-2 inhibitors
US5750558A (en) * 1996-06-06 1998-05-12 Abbott Laboratories Oxime derivatives of indole and indene compounds as inhibitors of prostaglandin biosynthesis
FR2749759B1 (en) * 1996-06-17 1999-11-26 Adir USE OF STRONTIUM SALTS FOR THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ARTHROSIS
US5945538A (en) * 1996-06-28 1999-08-31 American Cyanamid Company Ammonium oxazole and amino oxazolium intermediates, methods for the preparation thereof and the use therefor in the manufacture of insecticidal arylpyrroles
GB9615867D0 (en) * 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US5776967A (en) * 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
FR2751964B1 (en) * 1996-08-01 1998-10-30 Union Pharma Scient Appl NOVEL CARBOCYCLIC DIARYLMETHYLENE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THERAPEUTIC USES
US5830911A (en) * 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
US5681842A (en) * 1996-11-08 1997-10-28 Abbott Laboratories Prostaglandin synthase-2 inhibitors
ES2208964T3 (en) * 1996-12-10 2004-06-16 G.D. SEARLE & CO. PIRROLYL COMPOUNDS SUBSTITUTED FOR THE TREATMENT OF INFLAMMATION.
US5783597A (en) * 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
DE19710054A1 (en) * 1997-03-12 1998-09-17 Merck Patent Gmbh Pharmaceutical preparation
DE69810938T2 (en) 1997-04-11 2003-11-06 Grelan Pharmaceutical Co., Ltd. PYRAZOL DERIVATIVES AND COX INHIBITORS CONTAINING THEM
US5905089A (en) * 1997-04-14 1999-05-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Use of sesquiterpene lactones for treatment of severe inflammatory disorders
SE9703693D0 (en) * 1997-10-10 1997-10-10 Astra Pharma Prod Novel combination
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US6245797B1 (en) * 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
US6080876A (en) * 1997-10-29 2000-06-27 Merck & Co., Inc. Process for making phenyl heterocycles useful as COX-2 inhibitors
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
JP3256513B2 (en) 1998-02-11 2002-02-12 ファイザー製薬株式会社 Benzimidazole cyclooxygenase-2 inhibitor
GB9814316D0 (en) 1998-07-02 1998-09-02 Smithkline Beecham Plc Novel compounds
DE19837522A1 (en) * 1998-08-19 2000-02-24 Clariant Gmbh Use of metal carboxylates and sulfonates as charge control agents
US5980905A (en) * 1998-08-28 1999-11-09 Ambi Inc. Chromium polynicotinate compositions and uses thereof
US6077869A (en) * 1998-10-29 2000-06-20 Ortho-Mcneil Pharmaceutical, Inc. Aryl phenylhydrazides as selective COX-2 inhibitors for treatment of inflammation
US6232497B1 (en) * 1998-12-23 2001-05-15 Skw Trostberg Aktiengesellschaft Method for producing alkali metal and alkaline earth metal pyruvates
US6083969A (en) * 1999-10-20 2000-07-04 Ortho-Mcneil Pharaceutical, Inc. 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents
US20020018748A1 (en) * 2000-04-03 2002-02-14 Stanley Satz Method for targeted radiotherapy, pain palliation and imaging of osteoblastic skeletal tumors and composition therefore
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
US6365152B1 (en) * 2001-03-15 2002-04-02 Bovine Health Products, Inc. Scours treatment and method of making same
NO20014746D0 (en) * 2001-09-28 2001-09-28 Clas M Kjoelberg Pain reliever
US7273523B2 (en) * 2002-06-07 2007-09-25 Kyphon Inc. Strontium-apatite-cement-preparations, cements formed therefrom, and uses thereof
DE10225420A1 (en) * 2002-06-07 2003-12-24 Sanatis Gmbh Strontium apatite cement preparations, the cements formed therefrom and the use thereof
FR2844797B1 (en) * 2002-09-24 2004-10-22 Servier Lab NEW PROCESS FOR THE INDUSTRIAL SYNTHESIS OF ACID TETRAESTERS 5- [BIS (CARBOXYMETHYL)] - 3-CARBOXYMETHYL-4-CYANO-2- THIOPHENECARBOXYLIC AND APPLICATION TO THE SYNTHESIS OF BIVALENT HYDERS OF RANELATES ACID
FR2844795B1 (en) * 2002-09-24 2004-10-22 Servier Lab NEW PROCESS FOR THE INDUSTRIAL SYNTHESIS OF STRONTIUM RANELATE AND ITS HYDRATES
FR2844796A1 (en) * 2002-09-24 2004-03-26 Servier Lab New methyl 5-amino-4-cyano-3-(2-methoxy-2-oxoethyl)-2-thiophene-carboxylate useful as intermediate in the preparation of ranelic acid, its strontium, calcium or magnesium salts
PT1745791E (en) * 2003-05-07 2013-07-23 Osteologix As Treating cartilage/bone conditions with water-soluble strontium salts
US20060216358A1 (en) * 2003-05-07 2006-09-28 Christian Hansen Controlled release composition containing a strontium salt
DE602004002832T2 (en) * 2003-05-07 2007-06-06 Osteologix A/S TREATMENT OF CARTILAGE / BONE DISEASES WITH WATER-SOLUBLE STRONTIUM SALTS
AU2005216596B2 (en) * 2004-02-26 2011-03-24 Osteologix A/S Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions
WO2005108339A2 (en) * 2004-05-06 2005-11-17 Osteologix A/S High yield and rapid syntheses methods for producing metallo-organic salts
CA2570503A1 (en) * 2004-06-17 2005-12-29 Osteologix A/S A method of improving the medical treatment of pain
JP2008502609A (en) * 2004-06-17 2008-01-31 オステオロジックス エイ／エス Methods for improving treatment of rheumatoid arthritis and joint diseases
US20090137678A1 (en) * 2005-07-06 2009-05-28 Stephan Christgau High yield synthesis methods for producing organic salts of strontium

Also Published As

Publication number Publication date
HK1152493A1 (en) 2012-03-02
US20060275503A1 (en) 2006-12-07
WO2004098618A3 (en) 2005-03-24
CA2524610C (en) 2014-03-25
EP2266584B1 (en) 2012-09-05
PT1622630E (en) 2012-10-11
AU2011200693B2 (en) 2011-12-08
EP2266584A2 (en) 2010-12-29
EP2266584A3 (en) 2011-01-26
EP1622630A2 (en) 2006-02-08
EP1622630B1 (en) 2012-08-29
PT1745791E (en) 2013-07-23
AU2011200693A1 (en) 2011-03-10
US8623422B2 (en) 2014-01-07
CA2524610A1 (en) 2004-11-18
WO2004098618A2 (en) 2004-11-18
JP2011148814A (en) 2011-08-04
US20100143473A1 (en) 2010-06-10
PT2266585E (en) 2013-07-09
DK1622630T3 (en) 2012-12-17
JP2006525242A (en) 2006-11-09
AU2004237438B2 (en) 2011-01-20
PL2266584T3 (en) 2013-02-28
AU2004237438A1 (en) 2004-11-18
PL1622630T3 (en) 2013-01-31
CY1113264T1 (en) 2016-04-13
JP4861817B2 (en) 2012-01-25
PT2266584E (en) 2012-12-19
ES2393781T3 (en) 2012-12-28
DK2266584T3 (en) 2013-01-02
ES2394782T3 (en) 2013-02-05
SI1622630T1 (en) 2012-12-31
SI2266584T1 (en) 2012-12-31

Similar Documents

Publication Publication Date Title
CY1113286T1 (en) COMPOSITION WITH STRONTIUM AND VITAMIN D FOR PREVENTION Ή / TREATMENT OF STRAW Ή / BONE DISEASES
DE502007002101D1 (en) Medicinal products containing dobesilate calcium for the treatment and prophylaxis of tendon diseases
ATE496643T1 (en) USE OF ANTIOXIDANTS TO PREVENT OXIDATION AND TO REDUCE ACTIVE DEGRADATION IN MEDICAL ARTICLES CONTAINING ACTIVE INGREDIENTS
ATE331534T1 (en) USE OF TARGETED RADIUM 223 FOR PALLIATIVE AND THERAPEUTIC TREATMENT OF BONE CANCER
ATE316786T1 (en) TREATMENT OF MUCOSITIS
ATE238049T1 (en) USE OF CREATINE SUBSTANCES TO TREAT BONE AND CARTILAGE CELLS AND TISSUES
AR023130A1 (en) COMPOSITIONS TO PROMOTE GROWTH
DE60204966D1 (en) Use of cyclopamine for the manufacture of a medicament for the treatment of psoriasis
AR037556A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING A C1C-2 CHANNEL OPENER
DE60027209D1 (en) MEDICAMENT CONTAINS HYDROXYAPATITE FOR THE TREATMENT OF BONE WEBBLE DISEASES
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
BRPI0407178A (en) Osteogenic Pharmaceutical Composition
DE60309887D1 (en) COMBINATION OF AN AROMATASE WITH A BISPHOSPHONATE
ATE309817T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING TRKAIG2 FOR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER
BR0214196A (en) Method and composition for reducing the growth inhibiting activity of a cancer cell to treat a cancer patient
ATE198418T1 (en) PHARMACEUTICAL COMPOSITION FOR PROMOTING TISSUE HEALING AND REGENERATION AND PHARMACEUTICAL COMPOSITION
ATE401888T1 (en) USE OF TIGECYCLINE, ALONE OR IN COMBINATION WITH RIFAMPIN, TO TREAT OSTEOMYELITIS AND/OR SEPTIC ARTHRITIS
MXPA06007007A (en) Proline derivatives used as pharmaceutical active ingredients for the treatment of tumours.
DE50100833D1 (en) USE OF 2-METHYL-THIAZOLIDINE-2,4-DICARBONIC ACID AND / OR ITS PHYSIOLOGICALLY COMPATIBLE SALTS FOR PRODUCING A MEDICINE FOR TREATING CANCER DISEASES
ATE491442T1 (en) 1-PHENYL-2- DIMETHYLAMINOMETHYLCYCLOHEXANE COMPOUNDS FOR THE THERAPY OF DEPRESSIVE SYMPTOMS, PAIN AND INCONTINENCE
ES2110057T3 (en) MEDICINAL COMPOSITION CONTAINING TCF-II.
ATE345805T1 (en) CALCIUM TRIFLUOROCETATE WITH CYTOTOXIC EFFECT
DE50214008D1 (en) MEDICAMENT FOR THE TREATMENT OF TUMORS AND THEIR METASTASES USING A BINDING MOLECULE AGAINST THE BONE SIALOPROTEIN
EP1361905B8 (en) Matrix protein compositions for guided connective tissue growth
Debbarma et al. Fasciocutaneous flap as a method of soft tissue reconstruction in open tibial fractures